Living with LHON: Sight loss won’t stop James from seeing the worldWhen he was first told he had LHON, a rare genetic disease that would rob him of his Share XLiving with LHON: Sight loss won’t stop James from seeing the worldhttps://pharmaphorum.com/views-analysis-patients/living-with-lhon-sight-loss-wont-stop-james-from-seeing-the-world/
Patient Insights: Severe psoriasis & eczemaHoward Chang has lived with severe psoriasis and atopic dermatitis for almost 40 years since childhood. Now a Share XPatient Insights: Severe psoriasis & eczemahttps://pharmaphorum.com/views-analysis-patients/patient-insights-severe-psoriasis-eczema/
Embracing next generation patient centricityPharma has largely accepted the value and importance of patient centricity – now it’s time to scale it Share XEmbracing next generation patient centricityhttps://pharmaphorum.com/patients/embracing-next-generation-patient-centricity/
Addressing MS’ two-tier healthcare system is about ‘social justice’NICE has reversed its decision not to approve a new drug that offers hope to thousands of people Share XAddressing MS’ two-tier healthcare system is about ‘social justice’https://pharmaphorum.com/views-analysis-patients/ms-two-tier-healthcare-system/
A spotlight on patient-provider dialoguePatient-provider communication impacts both short- and long-term outcomes. Research demonstrates that poor communication leads to distress, uncertainty, internal Share XA spotlight on patient-provider dialoguehttps://pharmaphorum.com/views-and-analysis/behavioural-science-patient-provider-dialogue/
Are your internal processes drowning out the patient voice?Greater patient involvement is among the stated aims of the ABPI, so why do companies up and down Share XAre your internal processes drowning out the patient voice?https://pharmaphorum.com/views-analysis-patients/internal-processes-drowning-patient-voice/
Transparency creates fruitful pharma-patient group partnershipsCollaboration between pharma and patient organisations can yield fantastic results – but conflict of interest concerns can stop Share XTransparency creates fruitful pharma-patient group partnershipshttps://pharmaphorum.com/views-analysis-patients/transparency-creates-fruitful-pharma-patient-group-partnerships/
Fair market value for patientsFair Market Value (FMV) payment is not a new concept to the life science industry. It has for Share XFair market value for patientshttps://pharmaphorum.com/views-analysis-patients/fair-market-value-for-patients/
From poison to lifeline – how my views on chemotherapy changed as a cancer patientCancer survivor Brooke Gant tells us about her experiences with chemotherapy. In 2017, I started off being a Share XFrom poison to lifeline – how my views on chemotherapy changed as a cancer patienthttps://pharmaphorum.com/views-analysis-patients/from-poison-to-lifeline-how-my-views-on-chemotherapy-changed-as-a-cancer-patient/
